News | Brachytherapy Systems | January 05, 2017

Analysis Shows IORT Boost Effective Prior to Whole Breast Radiation

Results show low morbidity, excellent-to-good cosmetic results and low-grade adverse events for patients with early-stage breast cancer

iCAD, IORT boost, Xoft Axxent Electronic Brachytherapy System, intraoperative radiation therapy, whole breast radiation, early-stage breast cancer, SABCS 2016

January 5, 2017 — iCAD Inc. announced that researchers presented updated data on the use of intraoperative radiation therapy (IORT) with the Xoft Axxent Electronic Brachytherapy (eBx) System during the San Antonio Breast Cancer Symposium (SABCS), Dec. 6-10 in San Antonio, Texas. The data include results from a subset of patients who received IORT with the Xoft System as a boost prior to administration of whole breast radiation therapy (WBRT) in patients with early-stage breast cancer.

At the meeting, research was presented by Alam M. Nisar Syed, M.D., medical director, radiation oncology and endocurietherapy, Memorial Care Cancer Institute, Long Beach Memorial Medical Center. Syed’s findings include updated data on the treatment of 898 patients with early-stage breast cancer using IORT with the Xoft System at 26 hospitals in the United States and Portugal. The findings show that 90 percent of patients had excellent-to-good cosmesis with low rates of high-grade adverse events and recurrences two years post-treatment with Xoft IORT.

Of these 898 patients, 44 presented additional risk factors and were subsequently treated with WBRT, thus receiving an IORT boost dose prior to conventional treatment. This subset of patients was reviewed independently from the primary study, and Syed said he will continue to follow them as a separate subset for the duration of the 10-year study. The findings thus far show that IORT using the Xoft System as a tumor-bed boost at the time of lumpectomy is safe, with low morbidity, excellent-to-good cosmetic results and mostly low-grade adverse events.

“By identifying a subset of boost patients, our multi-center study not only showed positive clinical results, it highlighted the Xoft System’s versatility in the treatment of early-stage breast cancer,” said Syed. “IORT with the Xoft System offers patients many advantages, whether administered as monotherapy for smaller tumors or as a boost for women who require further treatment due to additional risk factors.”

For more information: www.xoftinc.com

Related Content

LOCalizer Implantable Tag Cleared for Long-Term Breast Lesion Placement
Technology | Breast Imaging | January 21, 2019
Hologic announced that the U.S. Food and Drug Administration (FDA) has cleared the LOCalizer radiofrequency...
Sponsored Content | Videos | Radiation Therapy | January 18, 2019
Join Chris Toth, president of Varian’s Oncology Systems business, for a look at product introductions for 2018 plus
Novel Technique May Significantly Reduce Breast Biopsies
News | Breast Biopsy Systems | January 17, 2019
A novel technique that uses mammography to determine the biological tissue composition of a tumor could help reduce...
Digital Mammography Increases Breast Cancer Detection
News | Mammography | January 16, 2019
The shift from film to digital mammography increased the detection of breast cancer by 14 percent overall in the United...
MIM Software Inc. Receives FDA 510(k) Clearance for Molecular Radiotherapy Dosimetry
Technology | Nuclear Imaging | January 16, 2019
MIM Software Inc. received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for molecular radiotherapy...
Artificial Intelligence Used in Clinical Practice to Measure Breast Density
News | Artificial Intelligence | January 15, 2019
An artificial intelligence (AI) algorithm measures breast density at the level of an experienced mammographer,...
Sponsored Content | Videos | Breast Imaging | January 11, 2019
Supplemental screening with ABUS helps personalize breast care for women with dense breasts and offers advanced...
Electronic Brachytherapy Effective in Long-Term Study of 1,000 Early-Stage Breast Cancers
News | Brachytherapy Systems, Women's Healthcare | January 07, 2019
Breast cancer recurrence rates of patients treated with intraoperative radiation therapy (IORT) using the Xoft Axxent...
Brachytherapy Alone Superior Treatment for Intermediate-Risk Prostate Cancer
News | Brachytherapy Systems | January 04, 2019
Patient-reported outcomes (PROs) indicated a significantly different clinician and patient-reported late toxicity...
Breast Cancer Patients Have Less Heart Damage With Heart Drug and Trastuzumab
News | Cardio-oncology | January 03, 2019
Breast cancer patients who take a heart drug at the same time as trastuzumab have less heart damage, according to a...